• News
  • BioTech

La Jolla Pharmaceutical obtains FDA approval for IND of kidney disease drug

La Jolla Pharmaceutical Co., a developer of therapeutics that target galectin-3, announced that the FDA Division of Cardiovascular and Renal Products approved the company's investigational new drug application (IND) for GCS-100.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!